Clinical trials showing symptom reduction used doses in the 6001200mg range with bioavailable formulations, not generic tablets
#2022-01018 and #2019-02397), the European Unions Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimers Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, Cure Alzheimers Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen fr Gamla Tjnarinnor, Hjrnfonden, Sweden (#FO2022-0270), the European Unions Horizon 2020 research and innovation programme under the Marie Skodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003)
Mechanism of Action BPC-157 exerts its therapeutic effects through multiple interconnected molecular pathways
Ultra White is a mesotherapeutic multi-component product with anti-aging and whitening effects
